Tobias Marquardt

This inventor holds 20 USPTO granted patents and 19 published patent applications, plus 2 CIPO patents and 15 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Bayer Intellectual Property Gmbh. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tobias Marquardt. Retrieved from https://idiyas.com/inventor/tobias-marquardt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 19)

% Patents Active = 40.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 15 (Patent Applications = 30)

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

Berlin, DE (2014 - 2016)
Wuppertal, DE (2016 - 2022)

Company Filing History:

18 out of 387

Bayer Pharma Aktiengesellschaft

patents

4 out of 12,268

Bayer Aktiengesellschaft

patents

2 out of 721

Bayer Intellectual Property Gmbh

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Soluble Guanylate Cyclase

Neutral Endopeptidase Inhibitor

Atrial Natriuretic Peptide

Muscarinic M2 Receptor

Pyrazolo Compounds

Imidazoquinoxalines

Angiotensin AII Antagonist

Tyrosine Threonine Kinase

Naphthyridine Derivatives

Cardiovascular Diseases

Pharmaceutical Preparations

Substituted Aminoquinoxalines

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427131 - Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof (2025-09-30),

2. 12331094 - Atrial natriuretic peptide engrafted antibodies (2025-06-17),

3. 11472803 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2022-10-18),

4. 11166932 - Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof (2021-11-09),

5. 10927109 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2021-02-23),

6. 10519154 - 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof (2019-12-31),

7. 10435403 - Positive allosteric modulators of muscarinic M2 receptor (2019-10-08),

8. 10292970 - Heteroaryl-substituted imidazo[1,2-A]pyridines and their use (2019-05-21),

9. 10214526 - Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof (2019-02-26),

10. 10174021 - Substituted pyrazolo[1,5-A]pyridines and their use (2019-01-08),

11. 10150773 - N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases (2018-12-11),

12. 9771360 - Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use (2017-09-26),

13. 9714266 - Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) (2017-07-25),

14. 9688699 - 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines (2017-06-27),

15. 9605008 - Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof (2017-03-28),

Title: The Innovative Work of Inventor Tobias Marquardt

Introduction: Tobias Marquardt, a prominent inventor based in Wuppertal, Germany, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 18 patents, he has focused primarily on developing novel compounds for the treatment and prevention of various cardiovascular and renal disorders.

Latest Patents: Among his recent innovations are the "7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides," which relate to new carboxamides and their application in creating medicaments aimed at cardiovascular and renal disease treatment. Another noteworthy patent involves "Stimulators and/or activators of soluble guanylate cyclase (sGC)" combined with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists. This invention targets multiple disorders, including chronic kidney failure and various other health complications, demonstrating Marquardt's commitment to advancing medical treatments.

Career Highlights: Marquardt has garnered extensive experience working with leading pharmaceutical companies. He has been associated with Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft, where he has further developed his expertise in medicinal chemistry and pharmacology. His contributions have not only added value to his employers but have also pushed the boundaries of pharmaceutical innovation.

Collaborations: Throughout his career, Marquardt has worked alongside skilled professionals such as Alexandros Vakalopoulos and Johannes-Peter Stasch. These collaborations have played a vital role in enhancing the depth and impact of his research, fostering an environment of innovation and creativity.

Conclusion: Tobias Marquardt is a distinguished inventor whose work in the pharmaceutical field has led to significant advancements in treatments for cardiovascular and renal disorders. His dedication to innovation, coupled with valuable collaborations, highlights his influence as an inventor in the industry. As he continues to pursue new discoveries, Marquardt remains a vital figure in the landscape of medical research and patent development.

Profile summary based on public USPTO records.